Suzhou Fengbei Biotech Stock Co., Ltd. (SHA:603334)
China · Delayed Price · Currency is CNY 30.57
-0.45 (-1.45%)
Jul 15, 2026, 3:00 PM CST
SHA:603334 Revenue
Suzhou Fengbei Biotech Stock had revenue of 1.11B CNY in the quarter ending March 31, 2026, with 97.64% growth. This brings the company's revenue in the last twelve months to 3.61B, up 70.48% year-over-year. In the year 2025, Suzhou Fengbei Biotech Stock had annual revenue of 3.17B with 62.77% growth.
Revenue (ttm)
3.61B
Revenue Growth
+70.48%
P/S Ratio
1.23
Revenue / Employee
9.15M
Employees
395
Market Cap
4.45B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.17B | 1.22B | 62.77% |
| Dec 31, 2024 | 1.95B | 220.23M | 12.75% |
| Dec 31, 2023 | 1.73B | 19.09M | 1.12% |
| Dec 31, 2022 | 1.71B | 413.11M | 31.89% |
| Dec 31, 2021 | 1.30B | 505.78M | 64.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 2.95B |
| Wuhan Hvsen Biotechnology | 1.74B |
| Hefei Lifeon Pharmaceutical | 1.55B |
| Kexing Biopharm | 1.46B |
| Shenzhen Weiguang Biological Products | 1.26B |
| ChemPartner PharmaTech | 1.14B |
| R&G PharmaStudies | 896.26M |
| Jiangsu Sihuan Bioengineering | 381.71M |